Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Metastasis | Research

MAL protein suppresses the metastasis and invasion of GC cells by interfering with the phosphorylation of STAT3

Authors: Zhijun Geng, Jing Li, Sandang Li, Yueyue Wang, Lele Zhang, Qiuzi Hu, Xinru Wang, Lugen Zuo, Xue Song, Xiaofeng Zhang, Sitang Ge, Jianguo Hu

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Gastric cancer (GC) is the fifth leading cause of cancer-related death worldwide and is accompanied by low diagnosis and survival rates. The molecular mechanism of GC must be elucidated to improve treatment strategies. Recent research has shown that the expression of myelin and lymphocyte (MAL) protein is reduced in a variety of adenocarcinomas and has the function of suppressing tumor growth. However, the mechanism by which MAL regulates the epithelial-mesenchymal transition (EMT) in GC remains unclear. Here, we showed that MAL expression was downregulated in specimens from patients with GC and was negatively correlated with the clinical stage. Gain- and loss-of function assays showed that interference with MAL significantly increased tumor cell proliferation, metastasis, invasion and the EMT. Overexpression of MAL significantly inhibited the malignant behavior of GC cells. Moreover, MAL suppressed the malignant behavior of GC cells by inhibiting STAT3 phosphorylation in vitro and in vivo. Our data indicate that MAL suppresses the malignant behavior of GC cells via the STAT3/EMT axis. This study also provides insights into the pathophysiological process of GC and a reference for diagnosis and treatment.
Literature
1.
go back to reference Tan P, Yeoh KG. Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology. 2015;149(5):1153-1162.e3.CrossRef Tan P, Yeoh KG. Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology. 2015;149(5):1153-1162.e3.CrossRef
2.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRef Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRef
3.
go back to reference Wu YY, Jiang JN, Fang XD, Ji FJ. STEAP1 regulates tumorigenesis and chemoresistance during peritoneal metastasis of gastric cancer. Front Physiol. 2018;9:1132.CrossRef Wu YY, Jiang JN, Fang XD, Ji FJ. STEAP1 regulates tumorigenesis and chemoresistance during peritoneal metastasis of gastric cancer. Front Physiol. 2018;9:1132.CrossRef
4.
go back to reference Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–14.CrossRef Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–14.CrossRef
5.
go back to reference Gao W, Yang J, Zhuo C, et al. A pipeline to call multilevel expression changes between cancer and normal tissues and its applications in repurposing drugs effective for gastric cancer. Biomed Res Int. 2020;2020:3451610.PubMedPubMedCentral Gao W, Yang J, Zhuo C, et al. A pipeline to call multilevel expression changes between cancer and normal tissues and its applications in repurposing drugs effective for gastric cancer. Biomed Res Int. 2020;2020:3451610.PubMedPubMedCentral
6.
go back to reference Caduff J, Sansano S, Bonnet A, Suter U, Schaeren-Wiemers N. Characterization of GFP-MAL expression and incorporation in rafts. Microsc Res Tech. 2001;52(6):645–55.CrossRef Caduff J, Sansano S, Bonnet A, Suter U, Schaeren-Wiemers N. Characterization of GFP-MAL expression and incorporation in rafts. Microsc Res Tech. 2001;52(6):645–55.CrossRef
7.
go back to reference Frank M, van der Haar ME, Schaeren-Wiemers N, Schwab ME. rMAL is a glycosphingolipid-associated protein of myelin and apical membranes of epithelial cells in kidney and stomach. J Neurosci. 1998;18(13):4901–13.CrossRef Frank M, van der Haar ME, Schaeren-Wiemers N, Schwab ME. rMAL is a glycosphingolipid-associated protein of myelin and apical membranes of epithelial cells in kidney and stomach. J Neurosci. 1998;18(13):4901–13.CrossRef
8.
go back to reference Lara-Lemus R. On the role of myelin and lymphocyte protein (MAL) in cancer: a puzzle with two faces. J Cancer. 2019;10(10):2312–8.CrossRef Lara-Lemus R. On the role of myelin and lymphocyte protein (MAL) in cancer: a puzzle with two faces. J Cancer. 2019;10(10):2312–8.CrossRef
9.
go back to reference Marazuela M, Acevedo A, Adrados M, García-López MA, Alonso MA. Expression of MAL, an integral protein component of the machinery for raft-mediated pical transport, in human epithelia. J Histochem Cytochem. 2003;51(5):665–74.CrossRef Marazuela M, Acevedo A, Adrados M, García-López MA, Alonso MA. Expression of MAL, an integral protein component of the machinery for raft-mediated pical transport, in human epithelia. J Histochem Cytochem. 2003;51(5):665–74.CrossRef
10.
go back to reference Petryszyn P, Chapelle N, Matysiak-Budnik T. Gastric cancer: where are we heading. Dig Dis. 2020;38(4):280–5.CrossRef Petryszyn P, Chapelle N, Matysiak-Budnik T. Gastric cancer: where are we heading. Dig Dis. 2020;38(4):280–5.CrossRef
11.
go back to reference Lu YJ, Geng ZJ, Sun XY, et al. Isoprenaline induces epithelial–mesenchymal transition in gastric cancer cells. Mol Cell Biochem. 2015;408(1–2):1–13.CrossRef Lu YJ, Geng ZJ, Sun XY, et al. Isoprenaline induces epithelial–mesenchymal transition in gastric cancer cells. Mol Cell Biochem. 2015;408(1–2):1–13.CrossRef
12.
go back to reference Puertollano R, Martín-Belmonte F, Millán J, et al. The MAL proteolipid is necessary for normal apical transport and accurate sorting of the influenza virus hemagglutinin in Madin–Darby canine kidney cells. J Cell Biol. 1999;145(1):141–51.CrossRef Puertollano R, Martín-Belmonte F, Millán J, et al. The MAL proteolipid is necessary for normal apical transport and accurate sorting of the influenza virus hemagglutinin in Madin–Darby canine kidney cells. J Cell Biol. 1999;145(1):141–51.CrossRef
13.
go back to reference Puertollano R, Alonso MA. MAL, an integral element of the apical sorting machinery, is an itinerant protein that cycles between the trans-Golgi network and the plasma membrane. Mol Biol Cell. 1999;10(10):3435–47.CrossRef Puertollano R, Alonso MA. MAL, an integral element of the apical sorting machinery, is an itinerant protein that cycles between the trans-Golgi network and the plasma membrane. Mol Biol Cell. 1999;10(10):3435–47.CrossRef
14.
go back to reference Wei B, Sun X, Geng Z, et al. Isoproterenol regulates CD44 expression in gastric cancer cells through STAT3/MicroRNA373 cascade. Biomaterials. 2016;105:89–101.CrossRef Wei B, Sun X, Geng Z, et al. Isoproterenol regulates CD44 expression in gastric cancer cells through STAT3/MicroRNA373 cascade. Biomaterials. 2016;105:89–101.CrossRef
15.
go back to reference Sleeman JP, Thiery JP. SnapShot: The epithelial–mesenchymal transition. Cell. 2011;145(1):162.e1.CrossRef Sleeman JP, Thiery JP. SnapShot: The epithelial–mesenchymal transition. Cell. 2011;145(1):162.e1.CrossRef
16.
go back to reference Pan YM, Wang CG, Zhu M, et al. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol Cancer. 2016;15(1):79.CrossRef Pan YM, Wang CG, Zhu M, et al. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol Cancer. 2016;15(1):79.CrossRef
17.
go back to reference Pan Y, Li Q, Cao Z, Zhao S. The SUMO E3 ligase CBX4 is identified as a poor prognostic marker of gastric cancer through multipronged OMIC analyses. Genes Dis. 2021;8(6):827–37.CrossRef Pan Y, Li Q, Cao Z, Zhao S. The SUMO E3 ligase CBX4 is identified as a poor prognostic marker of gastric cancer through multipronged OMIC analyses. Genes Dis. 2021;8(6):827–37.CrossRef
18.
go back to reference Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.CrossRef Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.CrossRef
19.
go back to reference de Marco MC, Martín-Belmonte F, Kremer L, et al. MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. J Cell Biol. 2002;159(1):37–44.CrossRef de Marco MC, Martín-Belmonte F, Kremer L, et al. MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. J Cell Biol. 2002;159(1):37–44.CrossRef
20.
go back to reference Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013;62(9):1315–26.CrossRef Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013;62(9):1315–26.CrossRef
21.
go back to reference Spaderna S, Schmalhofer O, Hlubek F, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006;131(3):830–40.CrossRef Spaderna S, Schmalhofer O, Hlubek F, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006;131(3):830–40.CrossRef
22.
go back to reference Soutto M, Chen Z, Bhat AA, et al. Activation of STAT3 signaling is mediated by TFF1 silencing in gastric neoplasia. Nat Commun. 2019;10(1):3039.CrossRef Soutto M, Chen Z, Bhat AA, et al. Activation of STAT3 signaling is mediated by TFF1 silencing in gastric neoplasia. Nat Commun. 2019;10(1):3039.CrossRef
23.
go back to reference Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16):4722–9.PubMed Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16):4722–9.PubMed
24.
go back to reference Copie-Bergman C, Gaulard P, Maouche-Chrétien L, Brière J, Haioun C, Alonso MA, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999;94(10):3567–75.CrossRef Copie-Bergman C, Gaulard P, Maouche-Chrétien L, Brière J, Haioun C, Alonso MA, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999;94(10):3567–75.CrossRef
25.
go back to reference Kohno T, Moriuchi R, Katamine S, Yamada Y, Tomonaga M, Matsuyama T. Identification of genes associated with the progression of adult T cell leukemia (ATL). Jpn J Cancer Res. 2000;91(11):1103–10.CrossRef Kohno T, Moriuchi R, Katamine S, Yamada Y, Tomonaga M, Matsuyama T. Identification of genes associated with the progression of adult T cell leukemia (ATL). Jpn J Cancer Res. 2000;91(11):1103–10.CrossRef
26.
go back to reference Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol. 2006;125(5):776–82.CrossRef Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol. 2006;125(5):776–82.CrossRef
27.
go back to reference Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, et al. Hypermethylated MAL gene—a silent marker of early colon tumorigenesis. J Transl Med. 2008;6:13.CrossRef Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, et al. Hypermethylated MAL gene—a silent marker of early colon tumorigenesis. J Transl Med. 2008;6:13.CrossRef
28.
go back to reference Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA Jr, Marks JR. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res. 2009;7(2):199–209.CrossRef Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA Jr, Marks JR. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res. 2009;7(2):199–209.CrossRef
29.
go back to reference Maruya S, Kim HW, Weber RS, Lee JJ, Kies M, Luna MA, et al. Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn. 2004;6(3):180–90.CrossRef Maruya S, Kim HW, Weber RS, Lee JJ, Kies M, Luna MA, et al. Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn. 2004;6(3):180–90.CrossRef
30.
go back to reference Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11(11):4044–55.CrossRef Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11(11):4044–55.CrossRef
31.
go back to reference Buffart TE, Overmeer RM, Steenbergen RD, Tijssen M, van Grieken NC, Snijders PJ, et al. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer. 2008;99(11):1802–7.CrossRef Buffart TE, Overmeer RM, Steenbergen RD, Tijssen M, van Grieken NC, Snijders PJ, et al. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer. 2008;99(11):1802–7.CrossRef
32.
go back to reference Choi B, Han TS, Min J, Hur K, Lee SM, Lee HJ, et al. MAL and TMEM220 are novel DNA methylation markers in human gastric cancer. Biomarkers. 2017;22(1):35–44.CrossRef Choi B, Han TS, Min J, Hur K, Lee SM, Lee HJ, et al. MAL and TMEM220 are novel DNA methylation markers in human gastric cancer. Biomarkers. 2017;22(1):35–44.CrossRef
Metadata
Title
MAL protein suppresses the metastasis and invasion of GC cells by interfering with the phosphorylation of STAT3
Authors
Zhijun Geng
Jing Li
Sandang Li
Yueyue Wang
Lele Zhang
Qiuzi Hu
Xinru Wang
Lugen Zuo
Xue Song
Xiaofeng Zhang
Sitang Ge
Jianguo Hu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03254-5

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine